The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Michael DeFiore - Evercore ISI - Analyst
: Thanks for taking my question and congrats on all the progress. Just two for me. One, on Avetide, just your recent commentary on Avetide for PBH
suggests that a large patient education campaign will be required. The question is this because the 8% of symptomatic patients don't necessarily
know they have PBH or will these educational efforts attempt to shore up and penetrate into less symptomatic patients have a follow up.
Question: Michael DeFiore - Evercore ISI - Analyst
: Very helpful.
My second question is on PSP. I just want to, as we head into the interim data, I just want to confirm the efficacy bogey on the PSP rating scale that
we should be looking for in the interim. Just given that the placebo group and many prior PSB trials declined by 10 points or 11 points over 52
weeks, should we expect roughly half of that in placebo?
Furthermore, sources say that the minimally clinically meaningful difference on the PSP rating scale over 6 months is around 6 points. So taken
together, should we expect maybe a flat 1% improvement in the drug treated arm.
Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 08, 2025 / 12:00PM, AMLX.OQ - Q1 2025 Amylyx Pharmaceuticals Inc Earnings Call
Question: Michael DeFiore - Evercore ISI - Analyst
: Very helpful. Thank you.
Question: Joel Beatty - Baird - Analyst
: Thanks. My question relates to a vexotide, GLP-1 agonists seem to have many favorable short term and long term health effects.
So, with that in mind in that context, what it gives you confidence that GLP1 antagonists like a vexide won't cause some type of safety issue, and
then I have a follow.
Question: Joel Beatty - Baird - Analyst
: Okay, that makes sense. And then as a follow up, I'm just, how are you currently thinking about potential business development activities?
| 
